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Hepatocellular carcinoma (HCC) is a cancer of global significance 
owing to its high incidence and extremely high mortality. It is 
the sixth most common cancer worldwide, with 854 000 new 
cases estimated to occur in 2015. Moreover, because of its high 
mortality, HCC is estimated to be the second, third or fourth most 
common cause of cancer deaths, causing ~810 000 deaths in 2015.[1] 
Since most HCCs occur in countries in Asia and Africa that do 
not have population-based cancer registries, it is estimated that 
there may be as much as a 40% undercount of HCC cases in these 
regions, resulting in a 20% underestimation of HCC incidence and 
mortality globally.[2] In addition to the lack of registries in sub-
Saharan Africa (SSA) countries, this underestimation is at least 
partially due to a general lack of appreciation of the high burden 
of disease and death from chronic viral hepatitis, resulting in a lack 
of population screening for viral hepatitis, lack of implementation 
of HCC surveillance in at-risk individuals, and lack of access to 
diagnostic imaging modalities and healthcare providers trained in 
HCC treatment, including hepatologists, interventional radiologists, 
and hepatobiliary surgeons.[3] HCC usually develops in the setting 
of chronic inflammation of the liver induced by viruses, toxins, 
metabolic liver disease or autoimmunity, and cirrhosis. The most 
important risk factors for HCC are chronic viral hepatitis B (HBV) 
and C (HCV), alcohol abuse and aflatoxin B1 (AFB1) exposure.[4] 
In middle and high income countries, obesity-related fatty liver 
disease is increasingly important as a cause of HCC. Due to the lack 
of surveillance and treatment capability in many high-incidence 
countries, HCC is typically diagnosed at late stages, and is thus 
associated with poor survival, with an estimated global mortality 
rate of 95%.[5] In this focused review we discuss the epidemiology of 
HCC, its association with viral hepatitis, and its pathogenesis. We 
also discuss the primary and secondary prevention of HCC along 
with challenges to implementation of comprehensive programmes to 
address the HCC burden in SSA counties. 
Methods 
We reviewed the published data comprehensively using PubMed 
and Google Scholar. Keywords used include: HCC, viral hepatitis, 
HBV, HCV, pathogenesis, primary and secondary prevention, and 
challenges in Africa. The quality of the evidence is indicated in 
parenthesis after each recommendation.  
Results
Epidemiology and association with viral hepatitis 
Viral hepatitis is a leading cause of disability and mortality 
worldwide, with a gradual increase in the number of deaths over the 
last few decades. The global yearly estimate of deaths due to viral 
hepatitis has increased from 0.89 million in 1990 to 1.45 million 
in 2013, higher than the estimated number of deaths from HIV, 
tuberculosis, or malaria.[6] Chronic viral infection is a major risk 
factor for HCC. Between 1990 and 2013, viral hepatitis increased 
from the tenth leading cause of death to the seventh leading cause 
of death globally.[6] HBV is the most common risk factor for HCC 
in most countries in SSA and Asia, while HCV is the most common 
risk factor for HCC in North America, Europe, Japan and Egypt.[7,8] 
Most countries in Africa have high (≥8%) or higher-intermediate 
(5 - 7.99%) prevalence of chronic HBV infection, with the exception 
of Algeria, Eritrea, Madagascar and the Seychelles, which have low 
(<2%) to lower-intermediate (2 - 4.99%) prevalence.[9] In South 
Africa (SA), the prevalence of chronic HBV was estimated as 6.7% 
of the general population. Chronic HBV occurs more commonly 
in black South Africans than other racioethnic population groups. 
This is partly because only a small percentage of babies born to 
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black mothers receive the HBV vaccine.[10] The prevalence of HBV 
infection also varies between regions of SA and between males and 
females. In older studies, HBV prevalences were estimated at 5 - 16% 
v. 8 - 9% in black males living in rural v. urban areas, respectively, 
and 4 - 12% v. 2.7 - 4% in black females living in rural v. urban areas, 
respectively.[10] In a recent study, the prevalence of HBV infection in 
healthy blood donors in SA was estimated at 0.66%.[11] 
 There is substantial global variation in the prevalence of chronic 
HCV infection. In Africa, the prevalence of chronic HCV infection 
is highest in Egypt, which has anti-HCV and viraemic prevalences of 
14.7% and 10.0%, respectively, rates that are higher than in almost all 
other countries. The high infection rates in Egypt are likely due to 
extensive iatrogenic transmission during national campaigns for the 
eradication of schistosomiasis.[12] Viraemic prevalence of HCC is also 
high (≥2.5%) in Central and Western SSA. For example, in Nigeria, 
the reported adult anti-HCV antibody and viraemic prevalences 
were 8.4% and 6.9%, respectively.[13] In Eastern and Southern SSA, 
viraemic prevalences are generally lower, varying between 0.75% 
and 1.25%. In SA and Zimbabwe, the anti-HCV prevalence was 1.7% 
and 1.6%, respectively, which was marginally higher than viraemic 
prevalence.[13] In North Africa and the Middle East, HCV prevalences 
vary substantially, with most countries having a viraemic prevalence 
between 0.75% and 1.25%.[13]
Given the substantial global variations in prevalence of the major 
risk factors, the epidemiology of HCC varies between regions and 
countries. The highest incidences of HCC are seen in regions with 
high prevalences of chronic HBV and HCV. In the most recent Global 
Burden of Disease Study, HCC is ranked first in cancer incidence 
in four countries (including Mongolia and three SSA countries: 
the Republic of the Gambia, Guinea, and Mali) and first in cancer 
mortality in 30 countries (including Egypt, Djibouti, Mozambique, 
and 24 other countries in central and western SSA).[1] In SA, HCC is 
ranked 14th in incidence and seventh in mortality.[1]
The incidence and mortality of HCC is generally higher in males 
than in females, with an incidence ratio of 2:1 to 6:1, depending on 
the region. In males, HCC is the most commonly diagnosed cancer in 
10 SSA countries (Mauritania, Republic of the Gambia, Mali, Burkina 
Faso, Cameroon, South Sudan, Democratic Republic of the Congo, 
Angola, Mozambique) and the most common cause of cancer deaths 
in most countries of western, eastern and central SSA.[1] Regionally, 
males in Central SSA have the third highest age-standardised 
incidence rate (ASIR) (per 100 000 person-years) of 24.4, after 
high-income Asia Pacific and East Asia, and the second highest age-
standardised death rate (ASDR) (per 100 000 person-years) of 29.4 
after East Asia.1 Similarly, females in Western SSA have the third 
highest ASIR of 10.9 after high-income Asia Pacific and East Asia, 
but the second highest ASDR of 10.9 after East Asia.[1] Currently, the 
incidence of HCC is underestimated in many countries, particularly 
developing countries, which is partially due to decreased access to 
care and poor reporting of health data. In 2012, at least 120 722 
cases of HCC were estimated to have been missed.[2] The revised 
global incidence was 12.0 per 100 000, while the reported incidence 
was 10.1 per 100 000.[2] The incidence of HCC was significantly 
underestimated in 78 countries, of which 34 (44%) were in Africa 
and included SA.[2] 
The age at the time of HCC diagnosis also varies based on 
aetiology of HCC and by region. In Africa, patients with HCC 
present at a younger age than in other regions of the world; 
therefore, surveillance of Africans with chronic HBV who are at risk 
for HCC is recommended from the age of 20 years.[2,14] In a study of 
a 1 552 HCC patients from 7 African countries, i.e. Nigeria, Ghana, 
Uganda, Malawi, Côte D’Ivoire, Sudan and Tanzania, the median 
age at the time of diagnosis was 42 years in patients with HBV, and 
43 years in patients with co-infection (HBV and HCV), 47 years 
in those with HCC of unknown aetiology, and 55 years in patients 
with HCV.[14] HBV-induced HCC was most frequently diagnosed 
between age 32.5 and 37.5 years, while HCV-induced HCC was 
mostly diagnosed between 57.5 and 62.5 years of age.[14] In the same 
study, the age of onset of HBV-induced HCC substantially varied 
between the countries included in the study. The median age of onset 
was youngest in Malawi (35 years) and highest in Sudan (58 years), 
with most countries ranging between 40 and 46 years. Compared 
with HCC patients in other regions, Africa has the youngest 
mean age (years) at diagnosis (45) compared with Japan (69), 
Europe (63 - 65), North America (62), Korea (57) and 
China (55 - 59), which results in the greatest number of years of 
potential life lost.[14-18] In a recently published US population-based 
study, country of birth (rather than race or ethnicity) had the largest 
impact on the age of diagnosis of HCC in the US population. The 
highest percentages of patients diagnosed with early onset HCC 
(younger than 50 years) were observed in patients born in West 
Africa (57%) followed by patients born in Oceania (24%) compared 
with 10 - 15% and <5% of patients born in Asia and Europe, 
respectively.[18] Birth in West, Central East or Southern Africa, or 
Oceania had the strongest associations with very early onset of 
HCC (age at the diagnosis younger than 40 years) and early onset of 
HCC.[18] On the other hand, birth in Japan, Canada, or Europe had 
the strongest inverse associations with early-onset HCC.[18] 
The underlying reasons for the young onset of HBV-induced 
HCC in Africa are incompletely understood. Potential causes of bias 
such as the younger population age distribution in Africa appear 
not to account entirely for the observed phenomenon. Data from 
Asia suggests that particular HBV genotypes and sub-genotypes are 
associated with increased viral replication, which in turn is associated 
with an increased risk of HCC. However, HBV-induced HCC in 
Africa is associated with different HBV genotypes and appears to 
occur in individuals with relatively low viral loads. The extent of the 
contribution of dietary Aflatoxin B1 exposure to the younger onset of 
HCC in Africa is also not clear.
Increasingly, non-alcoholic fatty liver disease (NAFLD) is 
recognised as an important contributor to liver carcinogenesis. 
While this is now most fully appreciated in North America, where 
fatty liver disease and the metabolic syndrome are now the largest 
single contributor to the burden of HCC, it is unclear how NAFLD 
may interact with HBV or HCV in determining the risk of HCC in 
Africa.[19] 
Survival of patients with HCC also varies between countries. 
In the Global HCC BRIDGE study[8] of ~18 000 patients, Taiwan 
and Japan, the countries with established and effective national 
HCC surveillance programs had substantially better median overall 
survival of patients with HCC. Over 84 months of follow up, median 
survival was not reached in Taiwan and was 60 months in Japan, as 
compared to regions or countries with less effective programs such 
as North America (33 months), South Korea (31 months), Europe 
(24 months), and China (23 months). In comparison, a study of the 
survival of patients with HCC in Africa showed substantially shorter 
median survival periods than was shown in the BRIDGE study. Egypt 
had the longest median survival (10.9 months) compared to 2.5 
months in a group of other African countries (Côte D’Ivoire, Ghana, 
Nigeria, Cameroon, Sudan, Ethiopia, Uganda and Tanzania).[20] 
Pathogenesis of HCC 
The molecular pathogenesis of HCC varies nearly as much as the 
epidemiology of this devastating disease. Fortunately, continual 
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progress in genetic and molecular analyses is yielding rapidly 
increasing amounts of data on the genetic and molecular alterations 
associated with development and progression of HCC. HCCs contain, 
on average, 20 - 100 mutations per genome, which is similar to the 
majority of solid tumours.[21] It is hoped that increased understanding 
of the HCC genomic landscape will lead to significant advances in 
tumour characterisation for targeted therapies. In this section, we 
outline the most significant genetic and genomic aberrations. 
The aetiology of HCC influences the genetic aberrations found 
in HCCs. HBV is a DNA virus that can induce HCC through 
several potential mechanisms: viral genome integration into the 
host genome; immune-mediated destruction and concomitant 
regeneration of HBV-infected hepatocytes; and the activity of HBV X 
(HBx) protein, a key regulatory protein in HBV replication that acts 
as a cofactor in the development of HCC.[22] In contrast, HCV appears 
to induce HCC by more indirect methods, mediating inflammation 
and inducing recurrent cycles of cell injury, repair and regeneration 
that result in premature senescence and activation of a fibrogenic 
repair response in the liver. The inflammatory environment 
produces high levels of genotoxic reactive oxygen species (ROS), 
which cause oncogenic mutations and mutational and epigenetic 
inactivation of tumor suppressors, contributing to the acquisition 
of the minimum complement of molecular alterations needed for 
the malignant phenotype.[23] The HCV viral core also plays a role in 
HCC carcinogenesis through inhibition of tumor suppressor genes, 
accelerating proliferative pathways, and generating ROS.[24] 
The most significant mutations associated with hepatocellular 
carcinoma include mutations in the telomerase reverse transcriptase 
(TERT) promoter (30 - 60%), tumor protein p53 (TP53) (18 - 50%), 
and β-catenin (CTNNB1) (18 - 40%).[25] In cirrhotic liver, while TERT 
mutations occur early in premalignant cells, CTNNB1 and TP53 
mutations occur only in progressed HCC.[26] In a normal liver, HCC 
can develop from hepatocellular adenomas (HCA), in which initiating 
CTNNB1 mutations predispose cells to malignant transformation, 
and TERT promotor mutations appear to occur as a second hit for 
full transformation.[26,27] Patients with HCC due to TERT promotor 
mutation tend to be older males and are more likely to be HCV-
positive.[28] TERT, which is one of the two major components of 
telomerase, functions to preserve chromosome telomere length and 
protect the telomeres at the ends of chromosomes from fusion with 
neighboring chromosomes, thus protecting the cell from chromosomal 
damage. In HCC, mutations in the TERT promoter region result in 
reactivation of TERT transcription, and thus cell immortalisation.
[29] The TERT region has been shown to be the most frequent site 
of recurrent HBV integration in the hepatocyte genome, and HBV 
integrations appear to substitute for TERT promoter mutations in 
mediating TERT reactivation.[30] HBV integrations can also mediate 
intra-chromosomal or inter-chromosomal rearrangements. TERT 
mutations and CTNNB1 mutations are more frequent in alcohol 
associated HCC, whereas HBV-induced HCC harbors more TP53 
mutations.[31] TERT promoter mutation frequency can also differ 
geographically, with mutation frequencies twice as high in African 
(53%) v. non-African (24%) tumours.[32] 
Mutations associated with the tumour suppressor gene, TP53, 
are the second most common genetic alteration in HCC. The 
mutational spectrum of p53 in HCC also varies across geographical 
regions.[33] For example, G:C to T:A transversions dominate p53 
mutations in HCCs occurring in African regions and China, but are 
much less common in North America. CTNNB1 mutations were 
found at double the frequency in HCC tumours with underlying 
TERT mutations, in contrast to those without TERT mutations 
(41% v. 21%).[27] Epigenetic changes are also important in HCC, 
as transcription of tumour suppressor genes can be inactivated by 
promoter hypermethylation and their mRNA levels and translation 
suppressed by microRNAs (miRNAs), which contributes to HCC 
carcinogenesis.[34] For example, the p16 tumor suppressor (encoded 
by CDKN2A) is frequently inactivated by hypermethylation in 
HCC, while upregulation of miR-210, miR-221, miR-224, and miR-
519d promotes HCC tumorigenesis by targeting specific genes and 
promoting cell cycle progression.[35-37] 
Primary and secondary prevention of HCC 
Primary and secondary prevention of HCC are particularly important 
in resource-limited countries, including most SSA countries, where 
imaging technology to identify early-stage disease and effective 
treatment options are both lacking. In these countries, the main focus 
should be on primary prevention in order to decrease risk factors such 
as viral hepatitis and cirrhosis, and secondary prevention through 
identification of patients with established risk factors and enrolling 
them in surveillance programmes for HCC, which are more cost 
effective and require more basic measures. Community and patient 
education by national education campaigns and through primary 
care providers on the most common causes of HCC, including viral 
hepatitis, alcohol abuse, aflatoxin exposure and metabolic syndrome, 
is an important strategy for primary prevention. Communities should 
be educated about routes of transmission and methods of protection 
against viral hepatitis, alcohol abuse screening and prevention, proper 
storage of grains and other harvested foods in hot, humid climates 
to prevent aflatoxin exposure, and obesity-associated liver disease. 
Given the strong association with viral hepatitis, prevention of new 
infections through applying universal precautions and avoiding 
unsafe medical procedures and injections,[38] HBV vaccination at 
birth and as part of the expanded programme of immunisation, post-
exposure prophylaxis and appropriate treatment of existing infections 
play key roles in the primary prevention of HCC. 
Secondary prevention or screening tests are applied in a continuous 
programme of ongoing surveillance to enhance detection of cancer at 
early stages during which treatment is more likely to be curative. 
The decision to enroll a patient in a surveillance programme for 
HCC is dependent on the estimated risk for HCC and the likelihood 
of benefit from therapy if HCC is discovered at an early stage. The 
American Association for the Study of Liver Diseases (AASLD), 
European Association for the Study of the Liver (EASL), and Asian 
Pacific Association for the Study of the Liver (APASL) guidelines 
consensually agree on surveillance for HCC in high risk patients 
(moderate/high evidence) (Table 1) using abdominal ultrasound 
with or without alpha fetoprotein measurement. High-risk patients 
include those with cirrhosis due to any aetiology (excluding those 
with Child-Pugh stage C who are not on a transplant waiting list 
given the low anticipated survival for these patients) and those with 
chronic viral HBV without cirrhosis if they were born in Africa or 
Asia and are over 20 years of age for Africans, over 40 years of age for 
Asian males, and over 50 years of age for Asian females. Individuals 
with a family history of HCC or with chronic active hepatitis 
are at particularly increased risk.[39] Ultrasonography, the imaging 
modality of choice for HCC surveillance, has a variable sensitivity 
(65 - 80%) and a specificity of >90%. The use of alpha-fetoprotein 
(AFP) for HCC screening has been controversial (Table 1), given its 
low sensitivity for diagnosis of early-stage disease and difficulties 
with specificity in individuals with active liver inflammation and 
regeneration. However, since US is insensitive in patients with central 
obesity and for those with infiltrative HCCs that do not have a 
nodular component, there is increasing consensus that the use of AFP 
in addition to US is warranted. In SSA and Asia, where many patients 
S38       August 2018, Vol. 108, (8 Suppl 1)
RESEARCH
are diagnosed with intermediate or advanced stage disease, almost 
all centres employ the AFP test and the World Gastroenterology 
Organization recommends its use for HCC surveillance.[3] No formal 
recommendations are provided for the use of other biomarkers 
such as the AFP-L3% and des-gamma carboxyprothrombin (DCP), 
and further research is encouraged.[40] The use of newer models for 
HCC diagnosis such as the GALAD score,[41-44] which incorporates 
patient Gender and Age in combination with the AFP-L3%, total 
AFP, and DCP may facilitate HCC diagnosis if it can be provided at 
low cost in SSA (GALAD Score Calculator: http://www.mayoclinic.
org/medical-professionals/model-end-stage-liver-disease/galad). 
The recommended surveillance interval is 6 months for suitable 
candidates.[40] It has been shown that surveillance leads to earlier 
detection of HCC, a higher likelihood of receiving curative treatment, 
and improvement in survival, even when adjusted for lead time bias. 
Countries such as Taiwan and Japan that have established effective 
national HCC surveillance programs have substantially better overall 
survival of patients with HCC compared with countries with less 
effective programs such as the US, Canada, most European countries, 
South Korea, China and SSA countries.[8]
Challenges in SSA countries
Since HBV is the most common cause of HCC worldwide, a full 
appreciation of the current status and secular trends in rates of 
chronic HBV infection, the consequent development of cirrhosis, 
end-stage liver disease, and HCC, as well as the outcomes of these 
complications is important for the development of a sound global 
health policy. With the recent publications of WHO Guidelines for 
evaluation and management of chronic HBV and chronic HCV, 
and resolutions by the World Health Assembly promoting the 
global eradication of chronic HBV and HCV, chronic viral hepatitis 
finally appears to be attracting the attention of the global health 
community.[45-47] However, large gaps remain, as major funders of 
global public health efforts still do not have robust programmes or 
a significant focus on eradication of chronic viral hepatitis and its 
sequelae.
Several limitations present in SSA countries lead to inadequate 
primary prevention in these countries. The majority of chronic 
HBV infections in Africa are due to perinatal or early childhood 
transmission, which can be successfully prevented by HBV 
vaccination within 24 hours of birth followed by two additional 
doses, as recommended by WHO.[48] Unfortunately, most SSA 
countries currently use the pentavalent childhood vaccination 
programme recommended by the Global Alliance for Vaccines and 
Immunization (GAVI), which begins at 6 - 8 weeks of age, and have 
not implemented the HBV vaccine dose at birth. Consequently, 
a proportion of children who do not receive the birth dose will 
already be HBV-positive by the time they receive the first dose of 
pentavalent vaccine. The average regional three-dose HBV vaccine 
coverage in Africa in 2015 was 76%, with substantial variation 
between countries; for example, coverage was 71% in SA and 98% 
in Rwanda and Tanzania. Although significantly improved since 
year 2000, when coverage was only 5%, it remains lower than the 
global coverage of 84%.[48] Several challenges have limited the 
administration of the birth dose. These include the high prevalence 
of home births with lack of resources to allow HBV vaccination at 
home, unreliable vaccine supplies, and lack of timely administration; 
for example; only 1% of infants in Nigeria and the Gambia were 
vaccinated within 24 hours of birth v. 50% of infants in Botswana.[48] 
Additionally, the relatively high cost for HBV vaccines in some African 
countries, despite the possibility of obtaining HBV vaccine at costs as 
low as USD0.30 per dose, and the global unavailability of an HCV 
vaccine are also challenges for the primary prevention of HCC.[49] 
Limitations in viral hepatitis diagnosis and treatment are also 
prevalent in low-resource countries, including: significant deficits in 
the numbers and capabilities of healthcare workers; lack of medical 
infrastructure, diagnostic methods and laboratories; unavailability of 
first line HBV treatments, e.g. tenofovir, which has a high barrier to 
resistance, necessitating the use of older medications with a higher 
risk of resistance; high costs of HCV treatment; and the required 
specific follow-up.[38] Several strategies have been suggested to 
improve viral hepatitis management in African countries: engaging 
decision makers from governmental and non-governmental 
organisations to find the needed resources within the country’s 
budget; developing a clear policy that recommends administration of 
the HBV vaccine to all newborn infants (not only those at high-risk) 
Table 1. International societies’ HCC screening guidelines
AASLD guidelines[40,51] EASL guidelines[4] APASL guidelines[52]
Screen the following groups (moderate 
evidence): 
1. Chronic HBV carriers who are:  
• Asian males >40 years old 
• Asian females >50 years old 
• African-born >20 years old  
• With family history of HCC 
• With high transaminases 
• With high viral loads 
2. Patients with cirrhosis (excluding those with 
child stage C who are not on transplantation 
waiting list) due to:   
Chronic HBV or HCV carriers 
Primary biliary cholangitis (stage 4) 
Other causes
Surveillance test/s: US with or without serum 
AFP level every 6 months (low evidence). 
Screen the following groups (moderate/high 
evidence):
1. Cirrhotic patients, Child-Pugh stage A and 
B (and C, who are on transplantation waiting 
list)
2. HBV carriers with: 
• Active hepatitis 
• Family history of HCC
3. Chronic hepatitis C with advanced liver 
fibrosis
Surveillance test/s: US every 6 months 
(moderate evidence). Serum AFP is 
suboptimal (moderate evidence). 
Screen the following groups (moderate 
evidence):
1. Cirrhotic patients due to different etiologies 
2. Chronic HBV carriers: 
• Asian males >40 years 
• Asian females >50 years 
• Africans aged >20 years 
• History of HCC in the family 
Surveillance test/s: the combination of US 
and serum AFP level biannually (moderate 
evidence). Measurement of AFP alone is not 
recommended (high evidence). 
HCC = hepatocellular carcinoma; AASLD = American Association for the Study of Liver Disease; EASL = European Association for the Study of the Liver; APASL = Asia Pacific Association for 
the Study of the Liver; HBV = hepatitis B virus; HCV = hepatitis C virus; US = ultrasound; AFP = alpha-fetoprotein.
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at birth, preferably within 24 hours, and definitely within 7 days;[50] 
establishing appropriate registries to document vaccination; engaging 
local community and religious leaders to encourage hospital rather 
than home deliveries, as well as using trained personnel to assist in 
home deliveries to ensure timely vaccination; storage of vaccines 
outside the cold chain (CC) in areas with unreliable CC given the 
stability of HBV vaccine at higher temperatures of 37 - 45°C for up to 
4 weeks; identifying the most effective therapy for HBV in the local 
setting; and decreasing the costs of hepatitis medications.[50] 
Despite the proven benefit for patients who are at risk of developing 
HCC, comprehensive surveillance programmes are lacking in SSA 
due to several challenges. Surveillance requires relatively expensive 
US machines and well-trained personnel. Lack of regional guidelines 
that take into consideration the limited resources in most SSA 
countries is another important challenge. Efforts should be spent to 
adapt the international guidelines (Table 1) and make them more 
applicable to SSA countries. Patient education about the importance 
of surveillance through national campaigns, primary care health 
workers, physicians and/or hepatologists, engaging health policy 
decision makers, finding financial resources in country budgets, 
and establishing training programs and documentation registries to 
monitor surveillance are all suggested strategies for improving HCC 
surveillance in SSA countries. 
Once HCC is diagnosed, there is also a critical need for local 
capability for the key curative and palliative treatments used for 
HCC, including surgical resection, local ablation, and locoregional 
chemoembolisation. There is a need to establish regional centers 
of excellence, to which patients with early and intermediate stage 
disease can be referred for treatment. There is also an urgent need 
for countries governments to approve treatments for advanced 
stage disease, and to negotiate lower costs for these often-expensive 
therapies. The recent advances in the development of targeted 
anticancer therapies, including sorafenib, regorafenib, lenvatinib and 
the immune checkpoint inhibitor nivolumab can only be deployed 
to reduce the burden of morbidity and mortality from HCC in sub 
Saharan Africa if there are ardent efforts to ensure their availability at 
prices that are within the reach of patients in this region. 
Conclusion 
HCC incidence correlates closely with the incidence of viral hepatitis B 
and C, which are the most important risk factors for HCC worldwide. 
The pathogenic mechanisms underlying HCC development, 
progression and metastasis are being actively deciphered, and novel 
discoveries hold promise for the development of effective systemic 
therapies for patients with intermediate and advanced stage disease. 
Primary prevention is an important strategy to control HCC in the 
resource-limited settings of most SSA countries. Finally, screening for 
HCC in high risk patients leads to detection of HCC at early curative 
stages, which in turn leads to improvement in overall survival. There 
is a critical need to build local capability in surgical resection, local 
ablation, and locoregional chemoembolisation, as well as a major 
need to address the cost of pharmaceutical treatments for patients 
with advanced stage disease.
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